How ADORA2B drives metastasis in pleomorphic sarcoma — and why it’s a tractable target
Spatial transcriptomics reveal crucial determinants of immune exclusion in non-small cell lung cancer: an analysis of the precision medicine BIP study
Background The tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) plays a pivotal role in determining response to immune checkpoint inhibitors (ICI). Immune contextures within the TME are classified into three main profiles based on CD8+ T-cell (CD8) infiltration: inflamed, excluded, and desert. Inflamed tumors are characterized by CD8 infiltration into tumor nests, reflecting […]
Why do some mature-TLS lung cancers resist immunotherapy? Two CAF subsets that drive primary resistance in NSCLC
Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Why IDO1 in inflamed TLS-positive lung tumors predicts immunotherapy response — and marks who might benefit from IDO1 inhibitors
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer
Background Monoclonal antibodies targeting programmed cell death-1, or PD-1, and its ligand PD-L1 have revolutionized the treatment of patients with advanced non-small cell lung cancer. However, most patients with advanced NSCLC display primary resistance to PD1/PD-L1 blockade. Identifying targetable alterations involved in resistance represents a promising approach to improve immunotherapy efficacy. TROP2 expression is associated […]
Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
Background Mature tertiary lymphoid structures have been reported to play a major role in the efficacy of PD-L1 blockade in non-small cell lung cancer. In TLS-positive NSCLC, the objective response rate to single-agent PD1/PD-L1 inhibition is similar to response rates observed in all-comer NSCLC patients treated with immune checkpoint inhibitors combined with chemotherapy. However, a […]
How tertiary lymphoid structures predict pembrolizumab response in soft-tissue sarcoma — and why plasma cells matter
High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas
Background The composition of the tumor microenvironment is a key determinant of effective anti-tumor immunity. In sarcomas, the presence of organized B and T cell aggregates, known as tertiary lymphoid structures, has recently been shown to predict response to immune checkpoint blockers. However, only a minority of patients derive clinical benefit from immune checkpoint […]
Why intratumoral CD163+ macrophages predict anti-PD-1 resistance in non-small cell lung cancer
